07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

APN201: Phase Ib data

A double-blind, placebo-controlled, Austrian Phase Ib trial in 20 breast cancer patients who received radiation therapy after breast-preserving surgery showed that once-daily APN201 given prior to radiation therapy was well tolerated with no treatment-related adverse...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Clinical News

APN201: Phase Ib started

Apeiron began a double-blind, placebo-controlled, Austrian Phase Ib trial to evaluate APN201 given prior to radiation therapy in about 20 patients. Apeiron has exclusive, worldwide rights to develop rhSOD from Polymun (see BioCentury, Nov. 15,...
08:00 , Feb 28, 2011 |  BioCentury  |  Product Development

Two for one in neuroblastoma

By activating multiple elements of the host's immune system, Apeiron Biologics AG believes its mAb fused to IL-2 will provide a one-two punch to neuroblastoma cells, without the toxic side effects of systemic IL-2 treatment....